Dynavax Technologies (DVAX) Competitors $11.41 -0.03 (-0.26%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$11.40 -0.01 (-0.04%) As of 04/15/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DVAX vs. ALKS, IONS, FOLD, LGND, MNKD, BCRX, INVA, NVAX, CLDX, and OPKShould you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), Celldex Therapeutics (CLDX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Dynavax Technologies vs. Alkermes Ionis Pharmaceuticals Amicus Therapeutics Ligand Pharmaceuticals MannKind BioCryst Pharmaceuticals Innoviva Novavax Celldex Therapeutics OPKO Health Dynavax Technologies (NASDAQ:DVAX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media prefer DVAX or ALKS? In the previous week, Alkermes had 15 more articles in the media than Dynavax Technologies. MarketBeat recorded 21 mentions for Alkermes and 6 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.62 beat Alkermes' score of 0.92 indicating that Dynavax Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dynavax Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alkermes 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, DVAX or ALKS? Alkermes has higher revenue and earnings than Dynavax Technologies. Alkermes is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDynavax Technologies$277.25M5.11-$6.39M$0.1863.39Alkermes$1.56B2.96$367.07M$2.1712.88 Is DVAX or ALKS more profitable? Alkermes has a net margin of 23.57% compared to Dynavax Technologies' net margin of 9.85%. Alkermes' return on equity of 30.80% beat Dynavax Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Dynavax Technologies9.85% 4.22% 2.67% Alkermes 23.57%30.80%19.09% Do analysts prefer DVAX or ALKS? Dynavax Technologies presently has a consensus target price of $21.50, indicating a potential upside of 88.43%. Alkermes has a consensus target price of $38.50, indicating a potential upside of 37.80%. Given Dynavax Technologies' higher possible upside, equities analysts plainly believe Dynavax Technologies is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynavax Technologies 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Alkermes 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility and risk, DVAX or ALKS? Dynavax Technologies has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Does the MarketBeat Community prefer DVAX or ALKS? Alkermes received 226 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.41% of users gave Alkermes an outperform vote while only 65.93% of users gave Dynavax Technologies an outperform vote. CompanyUnderperformOutperformDynavax TechnologiesOutperform Votes47665.93% Underperform Votes24634.07% AlkermesOutperform Votes70270.41% Underperform Votes29529.59% Do institutionals and insiders hold more shares of DVAX or ALKS? 97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 4.9% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAlkermes beats Dynavax Technologies on 12 of the 18 factors compared between the two stocks. Remove Ads Get Dynavax Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DVAX vs. The Competition Export to ExcelMetricDynavax TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42B$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio63.396.7921.7317.81Price / Sales5.11225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book2.375.866.464.00Net Income-$6.39M$141.86M$3.20B$247.23M7 Day Performance-2.89%8.98%6.54%7.26%1 Month Performance-17.74%-12.65%-8.55%-6.26%1 Year Performance-2.40%-11.99%10.33%-0.18% Dynavax Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DVAXDynavax Technologies4.3739 of 5 stars$11.41-0.3%$21.50+88.4%-2.4%$1.42B$277.25M63.39350Positive NewsGap DownALKSAlkermes4.7262 of 5 stars$29.49-1.9%$39.38+33.6%+16.3%$4.86B$1.56B13.591,800Short Interest ↓Analyst RevisionIONSIonis Pharmaceuticals3.971 of 5 stars$27.57+1.8%$57.70+109.3%-31.7%$4.38B$705.14M-9.07800Analyst ForecastFOLDAmicus Therapeutics4.0285 of 5 stars$7.15-4.7%$16.75+134.3%-35.3%$2.20B$528.30M-39.72480Positive NewsGap DownLGNDLigand Pharmaceuticals4.3379 of 5 stars$99.41-0.2%$147.00+47.9%+33.9%$1.91B$167.13M39.6180Analyst UpgradeNews CoveragePositive NewsGap DownMNKDMannKind2.2649 of 5 stars$4.69-1.1%$9.21+96.5%+12.6%$1.43B$285.50M67.00400Positive NewsGap DownBCRXBioCryst Pharmaceuticals4.1316 of 5 stars$6.79-0.6%$15.57+129.3%+58.5%$1.42B$450.71M-11.13530Gap DownINVAInnoviva4.3426 of 5 stars$17.51-1.2%$55.00+214.1%+25.8%$1.10B$358.71M25.38100Analyst UpgradeNews CoveragePositive NewsGap DownNVAXNovavax3.6003 of 5 stars$6.54+4.8%$18.00+175.2%+55.1%$1.05B$682.16M-2.891,990CLDXCelldex Therapeutics2.531 of 5 stars$15.73-0.3%$54.33+245.4%-53.0%$1.04B$7.02M-6.12150News CoveragePositive NewsGap DownOPKOPKO Health4.1219 of 5 stars$1.53-1.3%$2.75+79.7%+17.1%$1.03B$713.14M-8.053,930Options VolumeGap Down Remove Ads Related Companies and Tools Related Companies ALKS Competitors IONS Competitors FOLD Competitors LGND Competitors MNKD Competitors BCRX Competitors INVA Competitors NVAX Competitors CLDX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DVAX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DVAX Stock Free DVAX Stock Alerts